CNBC's Bertha Coombs reports on the race to treat drug-resistant infections.» Read More
The grant, for Cleveland BioLabs' Protectan CBLB502, is designed to fund "development leading to the acquisition" of an radiation countermeasure.
Ranbaxy Laboratories is no longer in the running to buy the generic drug business of Germany's Merck, India's CNBC TV18 reported Tuesday. Ranbaxy withdrew from the second round of bidding for the business, the television station said.
We're gearing up for a busy few days on the beat starting Friday. That's when biotech giant Genentech holds its annual analyst meeting in New York City. We'll be there. Last year the company put out new, boosted financial guidance in the middle of the trading day and it moved the stock. CEO Art Levinson told the crowd of analysts he liked to time it that way so they'll stick around for the whole day.
The test, called the Xpert EV test, can detect the condition in 2.5 hours compared with other products that can take as long as a week, the FDA said.
U.S. drug maker Bristol-Myers Squibb is moving assets of up to $25 billion from an Irish holding company, it said on Friday, fanning worries in Ireland that it is growing less competitive.
Stephen Collins continues to dig himself out of sub-million territory gaining $9,284 from Wednesday to end the day at $992,336.24. Here's how the news was handled on "Morning Call." Stephen is the celebrity stock picker for the show's second hour.
Last night I debated John Challenger of Challenger, Gray and Christmas, the firm that each year comes out with that March Madness lost wages study.
Here some of Thurday's big movers on European stock markets: Altadis, Imperial Tobacco, Pirelli, Cap Gemini, Swedish Match, Omega Pharma and AstraZeneca.
Bayer, one of the world's biggest chemical and pharmaceutical companies, said Thursday its fourth-quarter profit surged nearly seven times because of growth in its health care business.
U.S. health regulators have approved GlaxoSmithKline's pill Tykerb for patients with advanced breast cancer after other treatments have failed, a company spokeswoman said on Tuesday.
J.P. Garnier, GlaxoSmithKline's chief executive officer, told CNBC's "Squawk Box" Wednesday that he expects to make the company's new drug for advanced breast cancer available to U.S. patients "within a few days."
Our celebrity trading has begun--so it's time to see where the stars "stand." Not all have traded yet but for those that have, it seems their approach to investing is more conservative than the majority of our non-celeb leaders--with more stable companies and purchases spread across multiple stocks.
Indian drugmaker Ranbaxy Laboratories said Tuesday it has submitted a bid for the generics unit of Germany's Merck but did not disclose how much it was offering.
The chief executive of Merck received compensation the company valued at $8.04 million last year, according to a regulatory filing Monday.
Painkiller Vioxx contributed to an Idaho postal worker's heart attack, a jury in Atlantic City ruled Monday, reversing the verdict in the man's first trial and hitting drugmaker Merck with a total of $47.5 million in damages.
Drugmaker Schering-Plough is buying Organon Biosciences for about $14.5 billion. Organon is part of the Dutch paint and chemical company Akzo Nobel whose shares are at a new high today on the news. Schering Chairman and CEO Fred Hassan has been saying for quite some time that he's "very much in the deal flow" on company conference calls and in interviews with CNBC, so the fact that he's making a big acquisition doesn't come as a huge shock.
Smith & Nephew, a British maker of artificial hips, said Monday it agreed to buy Plus Orthopedics Holding, a private Swiss orthopedic company, for about 1.09 billion Swiss francs ($889 million; 617 million euros) in cash to boost its share of the orthopedic reconstruction market.
Here some of Monday's big movers on European stock markets: Akzo Nobel, Alliance Boots, ICI,Swisscom and DSG International.
Akzo Nobel said on Monday it was selling its drugs unit Organon BioSciences to Schering-Plough for 11 billion euros ($14.5 billion), dropping plans to float it in a public share offer.
The CEO of Akzo Nobel may be feeling like a lottery winner this morning after making a deal with Schering-Plough.